Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia

BACKGROUND: Paliperidone palmitate 3-monthly (PP3M) formulation is a long-acting, injectable antipsychotic treatment approved in many countries worldwide for the maintenance treatment of adult patients with schizophrenia. This single-arm, open-label, phase IIIb study evaluated the efficacy and safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Portilla, Maria Paz, Llorca, Pierre-Michel, Maina, Giuseppe, Bozikas, Vasilis P., Devrimci-Ozguven, Halise, Kim, Sung-Wan, Bergmans, Paul, Usankova, Irina, Pungor, Katalin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252374/
https://www.ncbi.nlm.nih.gov/pubmed/32518617
http://dx.doi.org/10.1177/2045125320926347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252374/
https://www.ncbi.nlm.nih.gov/pubmed/32518617
http://dx.doi.org/10.1177/2045125320926347

Ejemplares similares